1 in 3 members of Vida Health’s Clinical Obesity Management program lose 5% of their baseline weight in just 90 days without expensive GLP-1s.

Vida Health, a virtual, personalized obesity care provider that helps patients manage obesity and related conditions, today announced outcomes from its Clinical Obesity Management Program, which demonstrate that most patients do not require expensive GLP-1s to achieve sustainable, significant weight loss. Data from more than 18,000 participants demonstrates that Vida’s tailored treatment plans and commitment to responsible prescribing deliver better outcomes, lower costs, and immediate ROI for health plans and employers.

Key findings include:

• Smart, cost-saving GLP-1 utilization: Only 16% of new members who have not been on a GLP-1 in the past year are prescribed a GLP-1. With Vida’s thoughtful oversight, Vida only guides patients to GLP-1s when clinically appropriate and supports the rest of its members with effective, lower-cost alternatives. This leads to immediate cost savings for partners. With Vida, employers and health plans can avoid prescription costs up to $475 per member per month for those with obesity.
• Clinically significant weight loss, without high-cost medications: 1 in 3 members lose 5% of their baseline weight in just 90 days without a GLP-1, and 50% of those on anti-obesity medication alternatives see an equivalent 5% weight loss – demonstrating that effective outcomes do not always require high-cost therapies. In fact, 33% of members see success relying on behavior change alone.
• High medication adherence: Vida members have a 94% medication adherence rate among all medical weight loss members, which is nearly triple the average for GLP-1 users in the US.

Vida’s providers build strong relationships with members and use cognitive behavioral techniques to motivate meaningful lifestyle changes. Through medical nutrition therapy delivered by registered dietitians, members receive prescriptive nutritional guidance, nutritional support for managing medication side effects, and tools for long-term success. Physician oversight and personalized lifestyle coaching ensure ongoing progress, allowing for real-time adjustments to treatment plans and reinforcing behavior change, which drives better health outcomes, higher member satisfaction, and stronger ROI for GLP-1 therapy when needed.

"With or without medication, we know that encircling each member with a supportive, integrated care team makes all the difference,” said Richard Frank, MD, Chief Medical Officer at Vida Health. “Our latest outcomes data reinforces that treating the physical, mental, and emotional needs of each individual to find the right care pathway, which is often not GLP-1s, drives sustainable health outcomes while controlling costs."

To learn more about Vida’s Clinical Obesity Management program and the company’s virtual approach to personalized obesity care, visit www.Vida.com.

About Vida Health

Vida Health is a virtual, personalized obesity care provider that helps patients manage obesity and related conditions like diabetes, high blood pressure, anxiety, and depression with evidence-based treatment. Vida’s team of obesity medicine-certified physicians, registered dietitians, expert coaches, and licensed therapists take a whole-person approach leading to clinically meaningful body weight loss in one year. Practicing responsible prescribing, Vida supports patients, employers, and health plans by prioritizing proven behavior change and lifestyle interventions before introducing medications, ensuring that only those who really need anti-obesity medications receive them — helping to control costs. Employers and health plans avoid prescription costs up to $475 per member per month for those with obesity. Vida serves members in all 50 states and Washington D.C., offers services in both English and Spanish, and operates on a value-based pricing model, putting outcomes at the center of care. To learn more, visit www.Vida.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250520852766/en/